Managing Mild to Moderate Pediatric Atopic Dermatitis: Pathogenesis and Therapies for Improved Outcomes - A CE-certified webcast
This enduring, CE-certified webcast will address several important clinical practice gaps related to atopic dermatitis, including the importance of proper skin care in improving skin barrier dysfunction, current knowledge of inflammatory pathways that contribute to the pathogenesis of atopic dermatitis, as well as the safety and efficacy of current and emerging therapies for the treatment of mild to moderate atopic dermatitis.
This continuing education activity is administered by the National Association of Pediatric Nurse Practitioners (NAPNAP) as an Agency providing continuing education credit. Individuals who complete this program and earn a 70% or higher score on the posttest will be awarded 1.0 NAPNAP contact hours, of which 0.5 is pharmacology content.
This educational activity is co-sponsored by the National Association of Pediatric Nurse Practitioners and Spire Learning.
This activity is supported by an educational donation provided by Anacor Pharmaceuticals, Inc.
Participants are forbidden to reproduce, republish, redistribute, or resell this course in any other form. For copyright-related questions, please email your question to: firstname.lastname@example.org
Copyright 2017 © by Spire Learning.
LEVELS OF EVIDENCE
Two types of grades are provided for any treatment recommendations made in this presentation.
|Level of Evidence
|Strength of Clinical Recommendation
|I. Good-quality, patient-oriented evidence (ie, evidence measuring outcomes that matter to patients: morbidity, mortality, symptom improvement, cost reduction, and quality of life)
|A. Recommendation based on consistent and good-quality, patient-oriented evidence
|II. Limited-quality, patient-oriented evidence
|B. Recommendation based on inconsistent or limited-quality, patient-oriented evidence
|III. Other evidence including consensus guidelines, opinion, case studies, or disease-oriented evidence (ie, evidence measuring intermediate, physiologic, or surrogate endpoints that may or may not reflect improvements in patient outcomes)
|C. Recommendation based on consensus, opinion, case studies, or disease-oriented evidence
Source: American Academy of Dermatology Guidelines of Care for the Management of Atopic Dermatitis
Pediatric-focused advanced practice registered nurses (APRNs)
At the conclusion of this enduring activity, learners should be better able to:
- Summarize the role of skin barrier dysfunction and inflammatory responses in atopic dermatitis pathogenesis
- Recognize the symptoms of atopic dermatitis and how they differ in presentation in infants, children, and adolescents
- Evaluate the benefits and limitations of current therapies for mild to moderate atopic dermatitis
- Assess the efficacy and safety of emerging therapies and their potential role in treating atopic dermatitis
Judith A. J. O’Haver, PhD, RN, CPNP-PC
Pediatric Nurse Practitioner
Department of Dermatology
Phoenix Children’s Hospital
Judith A. J. O’Haver, PhD, RN, CPNP-PC, is a Pediatric Nurse Practitioner and Nurse Researcher at Phoenix Children’s Hospital in Arizona. She is also Clinical Assistant Professor in the Department of Child Health at the University of Arizona College of Medicine in Phoenix, and Assistant Clinical Professor in the Department of Pediatrics at Creighton University School of Medicine Phoenix Regional Campus. In addition,
Dr O’Haver holds an appointment as Faculty Associate at Arizona State University College of Nursing and Health Innovation. She earned her graduate degree in nursing from Arizona State University in Tempe, and her doctorate degree in nursing from the University of Arizona in Tucson. Dr O’Haver is a retired Lieutenant Colonel from the US Air Force Reserves.
Dr O’Haver’s research focuses on interventions with children who have been diagnosed with a chronic illness, the design and implementation of lifestyle interventions in children and adolescents, and pediatric dermatologic conditions. She is a frequent speaker at national and international meetings and has published more than 2 dozen peer-reviewed articles and coauthored book chapters in Pediatric Primary Care, Practice Guideline for Nurses, 3rd ed, and Textbook of Adolescent Health Care. Dr O’Haver is an active member of the nursing community, serving on several editorial boards and as a reviewer for peer-reviewed journals including Journal of Pediatric Health and Journal of the Dermatology Nurses Association. She also serves as Dermatology Clinical Expert for the National Association of Pediatric Nurse Practitioners (NAPNAP). Dr O’Haver has held offices in many professional organizations including the Society for Pediatric Dermatology PeDRA Ethics Committee and the NAPNAP National Research Committee. Throughout her career, she has been recognized with several honors including the 2011 Sigma Theta Tau Beta Upsilon Chapter Excellence in Research Award and the 2007 Phoenix Children’s Hospital Advanced Practice Nursing Excellence of the Year Award.
Research Support - Sub-investigator (institution): Anacor Pharmaceuticals, Inc
The opinions expressed in this educational activity are those of the faculty and do not represent those of the NAPNAP or Spire Learning. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.
This educational activity may contain discussion of published and/or investigational uses of therapies that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants are encouraged to consult appropriate resources for any product or device mentioned in this program.
CONFLICT OF INTEREST STATEMENTS
According to the disclosure policy of NAPNAP, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. Disclosures are as follows:
Please refer to the Faculty Presenter section for the faculty member’s affiliation and disclosure statement.
Educational Planning Committee
National Association of Pediatric Nurse Practitioners
Heather Keesing, MSN, RN, APRN; Laura Nelsen; Daniela Weitzman: No relevant financial relationships with any commercial interests.
Aisha Cobbs, PhD, and Christine Kocienda: No relevant financial relationships with any commercial interests.
Lori Williams, DNP, RN, RNC-NIC, CCRN, NNP-BC: No relevant financial relationships with any commercial interests.
- 1.00 Contact hours